Topics

Strimvelis, the Ex-vivo stem cell gene therapy to treat ADA-SCID

19:00 EDT 21 Aug 2017 | PharmaTelevision

Children born with ADA-SCID do not develop a healthy immune system so cannot fight off everyday infections, which results in severe and life-threatening illness. Without prompt treatment, the disorder often proves fatal within the child’s first year of life. ADA-SCID is estimated to occur in approximately 15 patients per year in Europe. Emily Culme-Seymour of GSK talks to Summer Park about Strimvelis, the Ex-vivo stem cell gene therapy to treat ADA-SCID, at ISCT 2017

Original Article: Strimvelis, the Ex-vivo stem cell gene therapy to treat ADA-SCID

NEXT ARTICLE

More From BioPortfolio on "Strimvelis, the Ex-vivo stem cell gene therapy to treat ADA-SCID"

Quick Search

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...